BRISTOL-MYERS SQUIBB COMPANY Future Amortization Expense, Year Three (Deprecated 2012-01-31)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Future Amortization Expense, Year Three (Deprecated 2012-01-31) of $263.00 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FutureAmortizationExpenseYearThree · last filed 2012-02-17
- BRISTOL-MYERS SQUIBB COMPANY future amortization expense, year three (deprecated 2012-01-31) for fiscal 2011 was $263.00M, a 48.59% increase from fiscal 2010.
- BRISTOL-MYERS SQUIBB COMPANY future amortization expense, year three (deprecated 2012-01-31) for fiscal 2010 was $177.00M.
| Period end | Future Amortization Expense, Year Three (Deprecated 2012-01-31) 12 month |
|---|---|
| 2011-12-31 | $263.00M 10-K · filed 2012-02-17 |
| 2010-12-31 | $177.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |